Serum amyloid A protein concentrations were monitored in 10 renal transplant recipients who required dialysis after transplantation because of an initially non-functioning graft. Fifteen rejection episodes were identified by repeated fine needle aspiration biopsies of the grafts. All rejections were characterised by pronounced increases in serum amyloid A concentrations, the mean peak value being 363 (SE 57) mg/l as compared with a mean preoperative concentration of 14 (5) mg/l. The rise in concentrations preceded the start of antirejection treatment by an average of 2-5 days in eight of the rejection episodes, in five episodes it occurred the same day, and in two episodes it occurred the next day. With exclusion of the predictable surgery induced rise in values, which peaked on the second postoperative day, there were 17 increases in amyloid A concentrations peaking at > 100 mg/l; in two cases they were not related to documented rejection.
Introduction
Identifying rejection of renal transplants in patients with acute tubular necrosis of the graft presents a major diagnostic difficulty. Tests of renal function cannot be used and the only practical aid in the diagnosis is histological or fine needle aspiration biopsy of the graft. We have observed that acute renal allograft rejection induces a dramatic increase in the serum amyloid A protein concentration in man' and that monitoring the serum amyloid A concentration in the postgrafting period provides a sensitive means of detecting rejection of the graft.' Our data further suggested that the test might be applied in transplant recipients requiring haemodialysis in the postgrafting period. We have now evaluated that question more closely and present our findings. unexplained.
The figure shows the course in a patient requiring haemodialysis for more than three weeks postoperatively. In this patient the first rise in serum amyloid A concentration was induced by surgery. It was followed by a diphasic rise, peaking on days 9-10 and 13. Transplant aspiration biopsy showed clear evidence of allograft rejection on the 12th postoperative day and antirejection treatment was therefore instituted. After a polyuric phase during the fifth postoperative week graft function stabilised. Monocyte, MpMmacrophage, Bl=lymphoid blast score in TAG.
Discussion
Elsewhere we have shown that the serum concentration of amyloid A increases dramatically in acute renal allograft rejection in man.' ' Since dialysis has no significant effect on serum amyloid A' and the concentration does not correlate with the degree of renal insufficiency6 we studied whether the serum amyloid A test might also be of help in diagnosing rejection in renal transplant recipients whose grafts do not function initially. A common cause of delayed function in cadaveric grafts is acute tubular necrosis.7 The diagnosis of hyperacute rejection and vascular complications is not usually difficult. In patients with acute tubular necrosis of the graft it is important to identify and treat concurrent acute rejections. Since laboratory tests that depend on renal function cannot be used, the diagnosis is chiefly based on histological or cytological biopsy studies. Our results show that monitoring the serum amyloid A concentration in the postgrafting period provides a new means of identifying and confirming acute allograft rejection in these cases.
Serum amyloid A is an acute phase reactant which is associated with high density lipoproteins in the circulation. 8 Under normal conditions the serum amyloid A concentration is usually <1 mg/l (range < 1-15 mg/i).9 In tissue injury and inflammation the concentration may rapidly increase by a factor of 100-1000.' 0-2 Other studies have shown that macrophage factors, which are closely related to interleukin 1, may induce hepatic synthesis of serum amyloid A. 13-"5 Since serum amyloid A is an acute phase protein an increase in the postgrafting period may imply both rejection and infection or surgical complication. We do not find the nonspecific nature of serum amyloid A a problem; a positive test result suggests the possibility of rejection and, in the absence of obvious infection or surgical complication, treatment may be started. Transplant aspiration biopsy may be used as a confirmatory test at that stage. A negative serum amyloid A test result-that is, no significant increase in concentration-on the other hand, argues strongly against rejection.2 The reproducibility of the measurement is high2 and the test is easily performed as a daily routine. It requires very small amounts of sample (10-20 [lI serum), and preliminary results may be read after as little as six hours. The surgery induced rise in concentration peaking on the second postoperative day is predictable and does not complicate interpretation.1 210 Since patients' baseline concentrations of serum amyloid A may vary postoperatively daily monitoring gives the best information. A rise in the concentration-not necessarily the absolute value is thus the most important criterion. We, however, find a limit of 100 mg/l useful: if the concentration does not exceed that value an acute rejection is unlikely. The numerical value of the concentration depends on several methodological factors, including the standard used. Hence each laboratory must standardise the test on acute phase sera with known values.
The cost of providing the serum amyloid A test as a daily routine is difficult to estimate for different countries and laboratories and is largely determined by the source of the antiserum. Nevertheless, it takes only about 15 minutes of a technician's time, and we estimate the total cost as £5-15 per patient a day.
We conclude that monitoring the serum amyloid A concentration offers a valuable non-invasive aid in the early diagnosis of acute allograft rejection, including that in renal transplant recipients who remain anuric or oliguric in the postgrafting period.
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